Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Lantheus Holdings, Inc. LNTH
$98.89
-$0.49 (-0.49%)
На 18:00, 12 мая 2023
+21.35%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
6760515066.00000000
-
week52high
99.97
-
week52low
47.46
-
Revenue
935061000
-
P/E TTM
230
-
Beta
0.65743900
-
EPS
0.39000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:00
Описание компании
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 05 авг 2022 г. |
| B. Riley Securities | Buy | 09 мая 2022 г. | |
| SVB Leerink | Outperform | Outperform | 02 мая 2022 г. |
| SVB Leerink | Outperform | Outperform | 24 февр 2022 г. |
| SVB Leerink | Outperform | Outperform | 29 июл 2021 г. |
| JonesTrading | Buy | 07 окт 2022 г. | |
| Mizuho | Buy | 13 окт 2022 г. | |
| SVB Leerink | Outperform | Outperform | 15 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Sabens Andrea | D | 60846 | 386 | 17 янв 2023 г. |
| Sabens Andrea | D | 61232 | 386 | 15 дек 2022 г. |
| Blanchfield Paul | D | 73968 | 2432 | 17 ноя 2022 г. |
| Sabens Andrea | D | 61618 | 386 | 15 ноя 2022 г. |
| Marshall Robert J. Jr. | D | 121065 | 5000 | 15 ноя 2022 г. |
| Niedzwiecki Daniel | D | 65143 | 3000 | 11 ноя 2022 г. |
| Heino Mary Anne | D | 672533 | 1516 | 08 ноя 2022 г. |
| Heino Mary Anne | D | 674049 | 4884 | 08 ноя 2022 г. |
| Heino Mary Anne | D | 678933 | 4750 | 08 ноя 2022 г. |
| Heino Mary Anne | D | 683683 | 2000 | 08 ноя 2022 г. |
Новостная лента
Lantheus Holdings, Inc. (LNTH) is Attracting Investor Attention: Here is What You Should Know
Zacks Investment Research
09 мая 2023 г. в 10:43
Recently, Zacks.com users have been paying close attention to Lantheus Holdings (LNTH). This makes it worthwhile to examine what the stock has in store.
Lantheus Holdings, Inc. (LNTH) Q1 2023 Earnings Call Transcript
Seeking Alpha
04 мая 2023 г. в 19:06
Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q1 2023 Results Conference Call May 4, 2023 8:00 AM ET Company Participants Mark Kinarney - Vice President of Investor Relations Mary Anne Heino - Chief Executive Officer Paul Blanchfield - President Bob Marshall - Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Securities Richard Newitter - Truist Securities Roanna Ruiz - SVB Securities Matt Taylor - Jefferies Yuan Zhi - B. Riley Justin Walsh - Jones Trading Larry Solow - CJS Securities Dave Turkaly - JMP Operator Good morning.
Why Shares of Lantheus Holdings Are Up Thursday
The Motley Fool
04 мая 2023 г. в 11:49
Lantheus credited increased sales of two of its imaging agents for the rise. The company has increased revenue for eight consecutive quarters.
What Awaits Lantheus Holdings (LNTH) This Earnings Season?
Zacks Investment Research
02 мая 2023 г. в 13:43
Lantheus Holdings' (LNTH) first-quarter results are likely to reflect solid top-line results on the back of robust product adoption.
Lantheus Holdings, Inc. (LNTH) Is a Trending Stock: Facts to Know Before Betting on It
Zacks Investment Research
24 апр 2023 г. в 10:39
Lantheus Holdings (LNTH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.